Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Introduction: Guidelines recommend postoperative venous thromboembolism (VTE) prophylaxis in colorectal cancer patients, as well as others at high risk of VTE. However, compliance, especially with injectable prophylaxis strategies remains challenging for patients and providers. Here, we evaluate the efficacy of apixaban versus enoxaparin in patients undergoing colorectal surgery (CRS) for postoperative VTE prophylaxis.
Methods: This is a retrospective study of institutional data conducted at a tertiary referral center. Data retrieved were from cases between January 2018 and May 2023. 1008 patients were included, 388 received enoxaparin, 620 received apixaban following discharge from abdominal or combined abdominal-perianal CRS. Patients on anticoagulation before surgical intervention were excluded as were those undergoing isolated stoma reversal or creation. The primary outcome was VTE in the 30 ds following discharge from CRS. Secondary outcome was bleeding, requiring either transfusion, intervention or readmission.
Results: Rates of VTE are low in both groups, but significantly higher in those who received enoxaparin than those who received apixaban (1.29% versus 0.16%, P = 0.023). Those receiving apixaban were significantly older, had longer operative times, underwent more minimally invasive procedures, and were more likely to have cancer (P < 0.01 for all instances). Postoperative bleeding rates did not differ between groups.
Conclusions: Patients undergoing CRS are effectively managed with apixaban as postdischarge VTE prophylaxis. VTE rates were lower in the apixaban group than in the enoxaparin group; additional randomized prospective trials are needed to validate this finding.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jss.2025.04.014 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Impact of drug utilization management strategies on the incidence and cost of clinical events in patients with non-valvular atrial fibrillation receiving DOACs in the US.
J Med Econ
September 2025
Health Economics and Outcomes Research Ltd., Cardiff, United Kingdom.
Background: Medicare plans employ drug utilization management strategies, including prior authorization (PA) and step therapy (ST), or formulary tier increases, to control spending. However, PA and ST can delay treatment access and encourage use of less effective/safe therapies, while formulary tier increases can lead to treatment switching/discontinuation due to higher patient out-of-pocket costs. This study modeled the impact of restricted access to direct oral anticoagulants (DOACs), and a tier increase for apixaban, on incidence and cost of clinical events in patients with non-valvular atrial fibrillation (NVAF) in the United States.
View Article and Find Full Text PDFEfficacy of Factor Xa Inhibitors Versus Placebo in Thromboprophylaxis for Cancer-Associated Thromboembolism: A Systematic Review and Meta-analysis.
Clin Appl Thromb Hemost
September 2025
The Maldives National University, Rahdhebai Hingun, Malé.
BackgroundCancer patients are at significantly increased risk of venous thromboembolism (VTE), a leading cause of morbidity and mortality in this population. While traditional anticoagulants like low-molecular-weight heparin (LMWH) and vitamin K antagonists (VKAs) are commonly used, their limitations have prompted growing interest in direct oral anticoagulants (DOACs), particularly Factor Xa inhibitors. However, concerns about bleeding risks persist.
View Article and Find Full Text PDFApixaban and Recurrent Stroke Risk With Left Ventricular Dysfunction: A Secondary Analysis of the ARCADIA Trial.
Stroke
September 2025
Department of Neurology, Emory School of Medicine, Atlanta, GA (D.J., F.N.).
Background: Major uncertainty remains about the relationship between left ventricular (LV) systolic dysfunction, recurrent stroke, and the optimal antithrombotic therapy for secondary stroke prevention in patients with recent stroke and LV systolic dysfunction.
Methods: We performed a post hoc analysis of data from the ARCADIA trial (Atrial Cardiopathy and Antithrombotic Drugs in Prevention After Cryptogenic Stroke), a randomized trial comparing apixaban versus aspirin for secondary stroke prevention in patients with cryptogenic stroke and atrial cardiopathy. Echocardiograms were sent from 185 enrolling sites in the United States and Canada for central review at the trial echocardiography laboratory.
Efficacy and safety of reduced-dose versus full-dose DOACs in extended treatment of VTE: A systematic review and meta-analysis.
J Thromb Thrombolysis
August 2025
Department of Medicine, Dow University of Health Sciences, Karachi, 74200, Pakistan.
Extended anticoagulation is recommended for venous thromboembolism (VTE) patients at high recurrence risk. However, the optimal long-term dosing strategy for direct oral anticoagulants (DOACs) remains uncertain. This meta-analysis compares the efficacy and safety of reduced-dose versus full-dose DOACs during extended-phase VTE treatment.
View Article and Find Full Text PDFClinical Outcomes of Switching From Warfarin to Apixaban or Rivaroxaban in Patients With Atrial Fibrillation: A Nationwide Multidatabase Study.
Circ Cardiovasc Qual Outcomes
August 2025
Harvard Medical School, Boston, MA (D.H.K., D.K., D.E.S., K.J.L.).
Background: The benefits of switching from warfarin to direct oral anticoagulants in atrial fibrillation remain unclear.
Methods: This retrospective study used the Medicare fee-for-service (2013-2020) and Optum Deidentified Clinformatics Data Mart databases (2013-2023). Among patients with atrial fibrillation who received warfarin for at least 180 days, we created 2 cohorts: (1) patients switching to apixaban versus continuing warfarin (the apixaban cohort) and (2) patients switching to rivaroxaban versus continuing warfarin (the rivaroxaban cohort).